BioNano Genomics (NASDAQ: BNGO) shares surged 8.7% in after-hours trading on Wednesday after the genomic analysis company announced a $3 million registered direct offering priced at-the-market under Nasdaq rules.
The San Diego-based firm entered into a definitive agreement with certain institutional investors to sell an aggregate of 9,881,113 shares of its common stock and accompanying warrants. The warrants include Series C warrants to purchase up to 9,881,113 shares at an exercise price of $0.3039 per share, exercisable five years after stockholder approval. Additionally, short-term Series D warrants were issued to purchase up to 9,881,113 shares at the same exercise price, expiring 18 months after stockholder approval.
The offering is expected to close on or around October 31, 2024, subject to customary closing conditions. BioNano intends to use the net proceeds, along with its existing cash and securities, for general corporate purposes such as working capital, research and development expenses, debt repayment, and capital expenditures.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。